Cea Soriano Lucía, Soriano-Gabarró Montse, García Rodríguez Luis A
Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain.
Epidemiology, Bayer Pharma AG, Berlin, Germany.
PLoS One. 2016 Jul 18;11(7):e0159179. doi: 10.1371/journal.pone.0159179. eCollection 2016.
We conducted three differently designed nested case-control studies to evaluate whether the protective effect of low-dose aspirin against colorectal cancer (CRC) is explained by selection bias.
Using a large validated UK primary care database, we followed different cohorts of patients, who varied in their demographic and clinical characteristics, to identify first ever cases of CRC. In Studies 1 and 2, two cohorts were followed, i) new users of low-dose aspirin at start of follow-up (N = 170,336 in Study 1, N = 171,527 in Study 2) and either ii) non-users of low-dose aspirin (Study 1, N = 170,336) or new users of paracetamol (Study 2, N = 149,597) at start of follow-up. In Study 3 a single cohort of individuals näive to low-dose aspirin at the start of observation was followed. Controls were selected using incidence sampling and logistic regression used to obtain an unbiased estimate of the incidence rate ratio (RR) with 95% confidence intervals (CIs). Low-dose aspirin exposure was analyzed 'as-treated' before the index date (CRC date for cases, random date for controls).
In the three studies, median (maximum) follow-up was 5.1 (12), 5.8 (12) and 7.5 (13) years, respectively. 3033 incident CRC cases were identified in Study 1, 3174 in Study 2, and 12,333 in Study 3. Current use of low-dose aspirin was associated with a significantly reduced risk of 34%, 29% and 31% in the three studies, respectively; corresponding RRs (95% CIs) were 0.66 (0.60-0.73), 0.71 (0.63-0.80) and 0.69 (0.64-0.74). In each study, significantly reduced risks of CRC were seen when low-dose aspirin was used for primary or secondary cardiovascular disease prevention, in both sexes, and across all age groups evaluated.
Low-dose aspirin is associated with a significantly reduced risk of CRC. The consistency of our findings across different studies makes selection bias an unlikely explanation.
我们开展了三项设计不同的巢式病例对照研究,以评估低剂量阿司匹林对结直肠癌(CRC)的保护作用是否可由选择偏倚来解释。
利用一个经过验证的大型英国初级保健数据库,我们追踪了不同队列的患者,这些患者的人口统计学和临床特征各异,以确定首例结直肠癌病例。在研究1和研究2中,追踪了两个队列,i)随访开始时低剂量阿司匹林的新使用者(研究1中N = 170,336,研究2中N = 171,527),以及ii)随访开始时低剂量阿司匹林的非使用者(研究1,N = 170,336)或对乙酰氨基酚的新使用者(研究2,N = 149,597)。在研究3中,追踪了一个在观察开始时未使用过低剂量阿司匹林的个体队列。使用发病抽样选择对照,并使用逻辑回归获得发病率比(RR)的无偏估计值及95%置信区间(CI)。在索引日期(病例的结直肠癌日期,对照的随机日期)之前,对低剂量阿司匹林暴露进行“按治疗情况”分析。
在这三项研究中,中位(最长)随访时间分别为5.1(12)年、5.8(12)年和7.5(13)年。在研究1中确定了3033例结直肠癌病例,研究2中为3174例,研究3中为12,333例。在这三项研究中,当前使用低剂量阿司匹林分别使风险显著降低34%、29%和31%;相应的RR(95%CI)分别为0.66(0.60 - 0.73)、0.71(0.63 - 0.80)和0.69(0.64 - 0.74)。在每项研究中,当使用低剂量阿司匹林进行原发性或继发性心血管疾病预防时,在所有评估的年龄组和两性中,结直肠癌风险均显著降低。
低剂量阿司匹林与结直肠癌风险显著降低相关。我们在不同研究中的结果一致性使得选择偏倚不太可能是一个解释。